106 results match your criteria Genetic Vaccines and Therapy[Journal]


Retraction: Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan.

Genet Vaccines Ther 2012 Oct 23;10(1):10. Epub 2012 Oct 23.

Bioinformatics Research Group, National Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-10-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522047PMC
October 2012
7 Reads

DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?

Genet Vaccines Ther 2012 Oct 9;10(1). Epub 2012 Oct 9.

Cork Cancer Research Centre, BioSciences Institute, University College Cork, Cork, Ireland.

Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based strategies can elicit anti-tumour responses, DNA vaccines present increased efficacy, inducing both humoural and cellular immunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-10-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502114PMC
October 2012
4 Reads

Targeting wild-type Erythrocyte receptors for Plasmodium falciparum and vivax Merozoites by Zinc Finger Nucleases In- silico: Towards a Genetic Vaccine against Malaria.

Genet Vaccines Ther 2012 Aug 31;10(1). Epub 2012 Aug 31.

Dept of Medical Microbiology, School of Biomedical Science, College of Health Sciences, Makerere University, P O Box 7072, Kampala, Uganda.

Unlabelled:

Background: Malaria causes immense human morbidity and mortality globally. The plasmodium species vivax and falciparum cause over 75 % clinical malaria cases. Until now, gene-based strategies against malaria have only been applied to plasmodium species and their mosquito-vector. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-10-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500210PMC
August 2012
7 Reads

Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model.

Genet Vaccines Ther 2012 Aug 31;10(1). Epub 2012 Aug 31.

Biotechnology & Environmental Biology, School of Applied Sciences, RMIT University, Bundoora West Campus, PO Box 71, Bundoora, Vic 3083, Australia.

Unlabelled:

Background: Liver fluke can infect cattle and sheep, and is also emerging as a human pathogen in developing countries. Cathepsin B (Cat B2) is a major cysteine protease secreted by the juvenile flukes. To enhance the immune responses of Cat B2, the cDNA sequence was fused with four different DNA vaccine vectors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-10-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505173PMC
August 2012
3 Reads

A brief review on dengue molecular virology, diagnosis, treatment and prevalence in Pakistan.

Genet Vaccines Ther 2012 Aug 28;10(1). Epub 2012 Aug 28.

Department of Bioinformatics and Biotechnology, Government College University (GCU), Faisalabad, Pakistan.

Dengue virus infection is a serious health problem infecting 2.5 billion people worldwide. Dengue is now endemic in more than 100 countries, including Pakistan. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-10-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478998PMC
August 2012
5 Reads

A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.

Genet Vaccines Ther 2012 Aug 8;10(1). Epub 2012 Aug 8.

Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Nobels väg 16, 171 77, Stockholm, Sweden.

Unlabelled:

Background: The use of optimized delivery devices has been shown to enhance the potency of DNA vaccines. However, further optimization of DNA vaccine delivery is needed for this vaccine modality to ultimately be efficacious in humans.

Methods: Herein we evaluated antigen expression and immunogenicity after intradermal delivery of different doses of DNA vaccines by needle or by the Biojector jet-injection device, with or without the addition of electroporation (EP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-10-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532290PMC
August 2012
41 Reads

Structure based sequence analysis & epitope prediction of gp41 HIV1 envelope glycoprotein isolated in Pakistan.

Genet Vaccines Ther 2012 06 20;10(1). Epub 2012 Jun 20.

University of the Punjab, Lahore, Pakistan.

Unlabelled:

Background: Gp41 is an envelope glycoprotein of human immune deficiency virus (HIV). HIV viral glycoprotein gp41, present in complex with gp120, assists the viral entry into host cell. Over eighty thousands individuals are HIV infected in Pakistan which makes about 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-10-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3524078PMC
June 2012
24 Reads

An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery.

Genet Vaccines Ther 2012 Jun 18;10(1). Epub 2012 Jun 18.

Departments of Pediatrics and Medical Genetics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Background: The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown to enhance drug delivery to bones.

Methods: In this study six-L aspartic acids (D6) were inserted into the AAV2 capsid protein sequence between amino acid residues 587 and 588. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-10-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416570PMC
June 2012
18 Reads

Treatment of adult MPSI mouse brains with IDUA-expressing mesenchymal stem cells decreases GAG deposition and improves exploratory behavior.

Genet Vaccines Ther 2012 Apr 20;10(1). Epub 2012 Apr 20.

Research center for gene therapy, Universidade Federal de São Paulo, São Paulo, Brazil.

Background: Mucopolysaccharidosis type I (MPSI) is caused by a deficiency in alpha-L iduronidase (IDUA), which leads to lysosomal accumulation of the glycosaminoglycans (GAGs) dermatan and heparan sulfate. While the currently available therapies have good systemic effects, they only minimally affect the neurodegenerative process. Based on the neuroprotective and tissue regenerative properties of mesenchymal stem cells (MSCs), we hypothesized that the administration of MSCs transduced with a murine leukemia virus (MLV) vector expressing IDUA to IDUA KO mouse brains could reduce GAG deposition in the brain and, as a result, improve neurofunctionality, as measured by exploratory activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-10-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404940PMC
April 2012
37 Reads

Molecular relationship between field and vaccine strain of measles virus and its persistence in Pakistan.

Genet Vaccines Ther 2012 Jan 30;10(1). Epub 2012 Jan 30.

Center of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore, Pakistan.

Background: Countrywide 5.9 million, 0-11 Month old children are immunized annually by EPI (Expended Program on Immunization) against 8 vaccine preventable diseases including measles and so on. Unfortunately the basic immunity centers are not uniform throughout the country. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-10-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298470PMC
January 2012
4 Reads

HCV entry receptors as potential targets for siRNA-based inhibition of HCV.

Genet Vaccines Ther 2011 Sep 6;9:15. Epub 2011 Sep 6.

Applied and Functional Genomics Lab, Centre of Excellence in Molecular Biology, University of the Punjab, Pakistan.

Background: Hepatitis C virus (HCV) is a major health concern with almost 3% of the world's population (350 million individuals) and 10% of the Pakistani population chronically infected with this viral pathogen. The current therapy of interferon-α and ribavirin against HCV has limited efficiency, so alternative options are desperately needed. RNA interference (RNAi), which results in a sequence-specific degradation of HCV RNA has potential as a powerful alternative molecular therapeutic approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179693PMC
September 2011
6 Reads

Occult HCV or delayed viral clearance from lymphocytes of Chronic HCV genotype 3 patients after interferon therapy.

Genet Vaccines Ther 2011 Sep 6;9(1):14. Epub 2011 Sep 6.

Institute of Biomedical and Genetic Engineering, Islamabad, Pakistan.

Background: A recently discovered occult HCV entity reported by various investigators seems to be highly controversial. Especially, the clinical significance of these findings remains uncertain. For optimal outcome of antiviral therapy, investigation of occult HCV needs a broad-based probe in order to investigate the results of viral therapy and its host/viral interaction. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-9-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184037PMC
September 2011
7 Reads

Biodistribution and blood clearance of plasmid DNA administered in arginine peptide complexes.

Genet Vaccines Ther 2011 Aug 17;9:13. Epub 2011 Aug 17.

Department of Life Science, Sogang University, Shinsu-Dong, Mapo, 121-742, Seoul, Republic of Korea.

Background: Peptide/DNA complexes have great potential as non-viral methods for gene delivery. Despite promising results for peptide-mediated gene delivery technology, an effective systemic peptide-based gene delivery system has not yet been developed.

Methods: This study used pCMV-Luc as a model gene to investigate the biodistribution and the in vivo efficacy of arginine peptide-mediated gene delivery by polymerase chain reaction (PCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170174PMC
August 2011
2 Reads

Establishment of stable Huh-7 cell lines expressing various hepatitis C virus genotype 3a protein: an in-vitro testing system for novel anti-HCV drugs.

Genet Vaccines Ther 2011 Jun 28;9(1):12. Epub 2011 Jun 28.

Molecular Virology Laboratory, National Centre of Excellence in Molecular Biology, 87-West Canal Bank Road ,Thokar Niaz Baig, Lahore-53700, University of the Punjab, Lahore, Pakistan.

Background: Hepatitis C virus (HCV) infection is the leading cause of chronic hepatitis which progresses to hepatocellular carcinoma (HCC) afflicting > 170 million people worldwide. HCV 3a is the most common genotype (about 70% of all genotypes) circulating in Pakistan. Expression of HCV individual gene of 3a would facilitate therapeutic and vaccines strategies against chronic HCV and liver Cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164222PMC
June 2011
35 Reads

Antiviral drugs against hepatitis C virus.

Genet Vaccines Ther 2011 Jun 23;9:11. Epub 2011 Jun 23.

Division of Molecular Medicine, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.

Hepatitis C virus (HCV) infection is a major worldwide problem causes acute and chronic HCV infection. Current treatment of HCV includes pegylated interferon-α (PEG IFN- α) plus ribavirin (RBV) which has significant side effects depending upon the type of genotype. Currently, there is a need to develop antiviral agents, both from synthetic chemistry and Herbal sources. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136400PMC
June 2011
4 Reads

Comparative analysis of macrophage associated vectors for use in genetic vaccine.

Genet Vaccines Ther 2011 Jun 18;9(1):10. Epub 2011 Jun 18.

National Institute of Virology, Pashan Campus, 130/1, Sus Road, Pashan, Pune, 411021, India.

Background: Antigen presentation by non professional antigen presenting cells (APC) can lead to anergy. In genetic vaccines, targeting the macrophages and APC for efficient antigen presentation might lead to balanced immune response. One such approach is to incorporate APC specific promoter in the vector to be used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146807PMC
June 2011
2 Reads

A comparison of multiple shRNA expression methods for combinatorial RNAi.

Genet Vaccines Ther 2011 Apr 17;9(1). Epub 2011 Apr 17.

Johnson and Johnson Research Pty Ltd, Level 4 Biomedical Building, 1 Central Avenue, Australian Technology Park, Eveleigh, NSW, 1430, Australia.

RNAi gene therapies for HIV-1 will likely need to employ multiple shRNAs to counter resistant strains. We evaluated 3 shRNA co-expression methods to determine their suitability for present use; multiple expression vectors, multiple expression cassettes and single transcripts comprised of several dsRNA units (aka domains) with each being designed to a different target. Though the multiple vector strategy was effective with 2 shRNAs, the increasing number of vectors required is a major shortcoming. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098768PMC
April 2011
6 Reads

Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism.

Genet Vaccines Ther 2011 Apr 8;9. Epub 2011 Apr 8.

Genetics Ph,D, Program, Program in Gene Therapy, 240 EMRB, The University of Iowa Roy J, and Lucille A, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242 USA.

Background: The envelope glycoprotein of lymphocytic choriomeningitis virus (LCMV) can efficiently pseudotype lentiviral vectors. Some strains of LCMV exploit high affinity interactions with α-dystroglycan (α-DG) to bind to cell surfaces and subsequently fuse in low pH endosomes. LCMV strains with low α-DG affinity utilize an unknown receptor and display unique tissue tropisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080791PMC
April 2011
2 Reads

In-vitro model systems to study Hepatitis C Virus.

Genet Vaccines Ther 2011 Apr 6;9. Epub 2011 Apr 6.

Division of Molecular Medicine, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.

Hepatitis C virus (HCV) is a major cause of chronic liver diseases including steatosis, cirrhosis and hepatocellular carcinoma. Currently, there is no vaccine available for prevention of HCV infection due to high degree of strain variation. The current treatment of care, Pegylated interferon α in combination with ribavirin is costly, has significant side effects and fails to cure about half of all infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083322PMC
April 2011
5 Reads

B cells Can Modulate the CD8 Memory T Cell after DNA Vaccination Against Experimental Tuberculosis.

Genet Vaccines Ther 2011 Mar 14;9. Epub 2011 Mar 14.

Department of Biochemistry and Immunology, Medical School of Ribeirão Preto, University of São Paulo, Brazil.

Background: Although B cells are important as antigen presenting cells (APC) during the immune response, their role in DNA vaccination models is unknown.

Methods: In this study in vitro and in vivo experiments were performed to evaluate the ability of B cells to protect mice against Mycobacterium tuberculosis challenge.

Results: In vitro and in vivo studies showed that B cells efficiently present antigens after naked plasmid pcDNA3 encoding M. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066104PMC
March 2011
8 Reads

In vitro evaluation of a double-stranded self-complementary adeno-associated virus type2 vector in bone marrow stromal cells for bone healing.

Genet Vaccines Ther 2011 Feb 27;9. Epub 2011 Feb 27.

New England Musculoskeletal Institute, Department of Orthopaedic Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA.

Background: Both adenoviral and lentiviral vectors have been successfully used to induce bone repair by over-expression of human bone morphogenetic protein 2 (BMP-2) in primary rat bone marrow stromal cells in pre-clinical models of ex vivo regional gene therapy. Despite being a very efficient means of gene delivery, there are potential safety concerns that may limit the adaptation of these viral vectors for clinical use in humans. Recombinant adeno-associated viral (rAAV) vector is a promising viral vector without known pathogenicity in humans and has the potential to be an effective gene delivery vehicle to enhance bone repair. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056728PMC
February 2011
3 Reads

Plasmid-encoded NP73-102 modulates atrial natriuretic peptide receptor signaling and plays a critical role in inducing tolerogenic dendritic cells.

Genet Vaccines Ther 2011 Jan 10;9(1). Epub 2011 Jan 10.

Department of Internal Medicine, Division of Allergy and Immunology, University of South Florida College of Medicine, Tampa, FL 33612, USA.

Background: Atrial natriuretic peptide (ANP) is an important endogenous hormone that controls inflammation and immunity by acting on dendritic cells (DCs); however, the mechanism remains unclear.

Objective: We analyzed the downstream signaling events resulting from the binding of ANP to its receptor, NPRA, and sought to determine what aspects of this signaling modulate DC function.

Methods: We utilized the inhibitory peptide, NP73-102, to block NPRA signaling in human monocyte-derived DCs (hmDCs) and examined the effect on DC maturation and induced immune responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025824PMC
January 2011
5 Reads

Hepatitis C virus genotype 3a with phylogenetically distinct origin is circulating in Pakistan.

Genet Vaccines Ther 2011 Jan 6;9(1). Epub 2011 Jan 6.

Division of Molecular Virology, National Centre of Excellence in Molecular Biology, University of the Punjab, 87-West Canal Bank Road Thokar Niaz Baig Lahore-53700, Pakistan.

Background: Hepatitis C virus (HCV) is one of the leading causes of viral hepatitis worldwide and its genotype 3a is predominant in vast areas of Pakistan.

Findings: The present study reports the first full sequence of HCV 3a isolate PK-1 from Pakistan. This nucleotide sequence was compared with six other HCV genotype 3a full length sequences from different regions of the world by using statistical methods of phylogenetic analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023652PMC
January 2011
3 Reads

Influence of insulators on transgene expression from integrating and non-integrating lentiviral vectors.

Genet Vaccines Ther 2011 Jan 4;9(1). Epub 2011 Jan 4.

CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière - UPMC/INERM UMR_S975/CNRS UMR7225, Equipe de Biotechnologie et Biothérapie, 83 boulevard de l'Hôpital, 75013 Paris, France.

Background: The efficacy and biosafety of lentiviral gene transfer is influenced by the design of the vector. To this end, properties of lentiviral vectors can be modified by using cis-acting elements such as the modification of the U3 region of the LTR, the incorporation of the central flap (cPPT-CTS) element, or post-transcriptional regulatory elements such as the woodchuck post-transcriptional regulatory element (WPRE). Recently, several studies evaluated the influence of the incorporation of insulators into the integrating lentiviral vector genome on transgene expression level and position effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-9-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025823PMC
January 2011
31 Reads

AAV2-mediated in vivo immune gene therapy of solid tumours.

Genet Vaccines Ther 2010 Dec 20;8. Epub 2010 Dec 20.

Cork Cancer Research Centre, Mercy University Hospital and Leslie C, Quick Jnr, Laboratory, University College Cork, Cork, Ireland.

Background: Many strategies have been adopted to unleash the potential of gene therapy for cancer, involving a wide range of therapeutic genes delivered by various methods. Immune therapy has become one of the major strategies adopted for cancer gene therapy and seeks to stimulate the immune system to target tumour antigens. In this study, the feasibility of AAV2 mediated immunotherapy of growing tumours was examined, in isolation and combined with anti-angiogenic therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-8-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016353PMC
December 2010
4 Reads

A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.

Genet Vaccines Ther 2010 Nov 1;8. Epub 2010 Nov 1.

Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia.

Background: Immunization of mice with tumor homogenate after combined treatment with cyclophosphamide (CP) and double-stranded DNA (dsDNA) preparation is effective at inhibition of growth of tumor challenged after the treatment. It was assumed that this inhibition might be due to activation of the antigen-presenting cells. The purpose was to develop improved antitumor strategy using mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-8-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987767PMC
November 2010
13 Reads

Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice.

Genet Vaccines Ther 2010 Aug 30;8. Epub 2010 Aug 30.

Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.

Background: Impaired wound healing in diabetes is related to decreased production of growth factors. Hence, gene therapy is considered as promising treatment modality. So far, efforts concentrated on single gene therapy with particular emphasis on vascular endothelial growth factor-A (VEGF-A). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-8-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939607PMC
August 2010
9 Reads

Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.

Genet Vaccines Ther 2010 Jul 16;8. Epub 2010 Jul 16.

Veterinary Laboratories Agency, Woodham Lane, New Haw, Addlestone, Surrey, KT15 3NB, UK.

Background: We have previously demonstrated protective efficacy against B. melitensis using formulations of naked DNA vaccines encoding genes ialB and omp25. The present study was undertaken to further understand the immune response generated by the protective vaccination regimens and to evaluate cationic liposome adsorption as a delivery method to improve vaccine utility. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-8-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2918601PMC
July 2010
4 Reads

Development of avian influenza virus H5 DNA vaccine and MDP-1 gene of Mycobacterium bovis as genetic adjuvant.

Genet Vaccines Ther 2010 May 24;8. Epub 2010 May 24.

Institute of Bioscience, University Putra Malaysia, Serdang 43400, Selangor, Malaysia.

Background: Studies have shown that DNA vaccines can induce protective immunity, which demonstrated the high potential of DNA vaccines as an alternative to inactivated vaccines. Vaccines are frequently formulated with adjuvants to improve their release, delivery and presentation to the host immune system.

Methods: The H5 gene of H5N1 virus (A/Ck/Malaysia/5858/04) was cloned separately into pcDNA3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-8-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887864PMC
May 2010
50 Reads

Recombinant lambda-phage nanobioparticles for tumor therapy in mice models.

Genet Vaccines Ther 2010 May 12;8. Epub 2010 May 12.

Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, 14115-111 Iran.

Lambda phages have considerable potential as gene delivery vehicles due to their genetic tractability, low cost, safety and physical characteristics in comparison to other nanocarriers and gene porters. Little is known concerning lambda phage-mediated gene transfer and expression in mammalian hosts. We therefore performed experiments to evaluate lambda-ZAP bacteriophage-mediated gene transfer and expression in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-8-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890663PMC
May 2010
15 Reads
5 Citations

Protection against the allergic airway inflammation depends on the modulation of spleen dendritic cell function and induction of regulatory T cells in mice.

Genet Vaccines Ther 2010 Mar 24;8. Epub 2010 Mar 24.

Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.

Background: Allergen-induced imbalance of specific T regulatory (Treg) cells and T helper 2 cells plays a decisive role in the development of immune response against allergens.

Objective: To evaluate effects and potential mechanisms of DNA vaccine containing ovalbumin (OVA) and Fc fusion on allergic airway inflammation.

Methods: Bronchoalveolar lavage (BAL) levels of inflammatory mediators and leukocyte infiltration, expression of CD11c+CD80+ and CD11c+CD86+ co-stimulatory molecules in spleen dendritic cells (DCs), circulating CD4+ and CD8+ T cells, Foxp3+ in spleen CD4+ T cells and spleen CD4+ T cells were measured in OVA-sensitized and challenged animals pretreated with pcDNA, OVA-pcDNA, Fc-pcDNA, and OVA-Fc-pcDNA. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-8-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861055PMC
March 2010
5 Reads

Optimised electroporation mediated DNA vaccination for treatment of prostate cancer.

Genet Vaccines Ther 2010 Feb 5;8(1). Epub 2010 Feb 5.

Cork Cancer Research Centre, Mercy University Hospital, Cork, Ireland.

Background: Immunological therapies enhance the ability of the immune system to recognise and destroy cancer cells via selective killing mechanisms. DNA vaccines have potential to activate the immune system against specific antigens, with accompanying potent immunological adjuvant effects from unmethylated CpG motifs as on prokaryotic DNA. We investigated an electroporation driven plasmid DNA vaccination strategy in animal models for treatment of prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-8-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829554PMC
February 2010
3 Reads

Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression.

Genet Vaccines Ther 2009 Dec 30;7:13. Epub 2009 Dec 30.

Neumedicines Inc, Pasadena, California 91107, USA.

Background: Murine retroviral vectors have been used in several hundred gene therapy clinical trials, but have fallen out of favor for a number of reasons. One issue is that gene expression from viral or internal promoters is highly variable and essentially unregulated. Moreover, with retroviral vectors, gene expression is usually silenced over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809042PMC
December 2009
12 Reads

Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice.

Genet Vaccines Ther 2009 Aug 14;7:12. Epub 2009 Aug 14.

Novosibirsk State University, Novosibirsk, Russia.

Background: When cyclophosphamide and preparations of fragmented exogenous genomic double stranded DNA were administered in sequence, the regressive effect on the tumor was synergic: this combined treatment had a more pronounced effect than cyclophosphamide alone. Our further studies demonstrated that exogenous DNA stimulated the maturation and specific activities of dendritic cells. This suggests that cyclophosphamide, combined with DNA, leads to an immune response to the tumors that were grafted into the subjects post treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732619PMC
August 2009
11 Reads

Dietary restriction abrogates antibody production induced by a DNA vaccine encoding the mycobacterial 65 kDa heat shock protein.

Genet Vaccines Ther 2009 Jul 16;7:11. Epub 2009 Jul 16.

Department of Microbiology and Immunology, Biosciences Institute, São Paulo State University (UNESP), Botucatu, São Paulo, 18618-000, Brazil.

Background: Protein-calorie malnutrition (PCM) is the most common type of malnutrition. PCM leads to immunodeficiency and consequent increased susceptibility to infectious agents. In addition, responses to prophylactic vaccines depend on nutritional status. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-7-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717961PMC
July 2009
6 Reads

Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models.

Genet Vaccines Ther 2009 Jun 21;7:10. Epub 2009 Jun 21.

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Guo Xue Xiang, No 37, Chengdu, Sichuan 610041, PR China.

Background: Vascular endothelial growth factor (VEGF) and its receptor, VEGFR-2 (Flk-1/KDR), play a key role in tumor angiogenesis. Blocking the VEGF-VEGFR-2 pathway may inhibit tumor growth. Here, we used human VEGFR-2 as a model antigen to explore the feasibility of immunotherapy with a plasmid DNA vaccine based on a xenogeneic homologue of this receptor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224891PMC
June 2009
3 Reads

AAV-mediated gene therapy for metabolic diseases: dosage and reapplication studies in the molybdenum cofactor deficiency model.

Genet Vaccines Ther 2009 Jun 18;7. Epub 2009 Jun 18.

Institut für Humangenetik der Universität Göttingen, Heinrich-Düker-Weg 12, 37073 Göttingen, Germany.

In a mouse model for molybdenum cofactor deficiency as an example for an inherited metabolic disease we have determined the dosage of recombinant AAV necessary to rescue the lethal deficiency phenotype. We demonstrated long-term expression of different expression cassettes delivered in a chimeric AAV capsid of serotype 1/2 and compared different routes of application. We then studied the effect of double and triple injections at different time points after birth and found a short neonatal window for non-response of the immune system. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-7-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702341PMC
June 2009
5 Reads

Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5.

Genet Vaccines Ther 2009 Jun 10;7. Epub 2009 Jun 10.

Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine and UCLA AIDS Institute, University California, Los Angeles, Los Angeles, California 90095, USA.

Background: The use of shRNAs to downregulate the expression of specific genes is now relatively routine in experimentation but still hypothetical for clinical application. A potential therapeutic approach for HIV-1 disease is shRNA mediated downregulation of the HIV-1 co-receptor, CCR5. It is increasingly recognized that siRNAs and shRNAs can have unintended consequences such as cytotoxicities in cells, particularly when used for long term therapeutic purposes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701936PMC
June 2009
7 Reads

Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Genet Vaccines Ther 2009 Jun 8;7. Epub 2009 Jun 8.

Latvian Biomedical Research and Study Centre, Ratsupites 1, Riga, LV-1067, Latvia.

Background: Hepatitis C core protein is an attractive target for HCV vaccine aimed to exterminate HCV infected cells. However, although highly immunogenic in natural infection, core appears to have low immunogenicity in experimental settings. We aimed to design an HCV vaccine prototype based on core, and devise immunization regimens that would lead to potent anti-core immune responses which circumvent the immunogenicity limitations earlier observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702340PMC
June 2009
12 Reads

Assessment of methods and analysis of outcomes for comprehensive optimization of nucleofection.

Genet Vaccines Ther 2009 May 11;7. Epub 2009 May 11.

NIAID, NIH, DHHS, Bldg 33, Room 3W10A.6, 33 North Drive, MSC 3203 Bethesda, Maryland 20892-3203, USA.

Background: Nucleofection is an emerging technology for delivery of nucleic acids into both the cytoplasm and nucleus of eukaryotic cells with high efficiency. This makes it an ideal technology for gene delivery and siRNA applications. A 96-well format has recently been made available for high-throughput nucleofection, however conditions must be optimized for delivery into each specific cell type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683797PMC
May 2009
4 Reads

Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours.

Genet Vaccines Ther 2009 Mar 9;7. Epub 2009 Mar 9.

Cork Cancer Research Centre, Mercy University Hospital, Leslie C Quick Junior Laboratory, University College Cork, Cork, Ireland.

The most common cause of death of cancer sufferers is through the occurrence of metastases. The metastatic behaviour of tumour cells is regulated by extracellular growth factors such as hepatocyte growth factor (HGF), a ligand for the c-Met receptor tyrosine kinase, and aberrant expression/activation of the c-Met receptor is closely associated with metastatic progression. Nk4 (also known as Interleukin (IL)32b) is a competitive antagonist of the HGF c-Met system and inhibits c-Met signalling and tumour metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669068PMC
March 2009
2 Reads

A new plasmid vector for DNA delivery using lactococci.

Genet Vaccines Ther 2009 Feb 10;7. Epub 2009 Feb 10.

Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (ICB-UFMG), Belo Horizonte - MG, Brasil.

Background: The use of food-grade lactococci as bacterial carriers to DNA delivery into epithelial cells is a new strategy to develop live oral DNA vaccine. Our goal was to develop a new plasmid, named pValac, for antigen delivery for use in lactococci. The pValac plasmid was constructed by the fusion of: i) a eukaryotic region, allowing the cloning of an antigen of interest under the control of the pCMV eukaryotic promoter to be expressed by a host cell and ii) a prokaryotic region allowing replication and selection of bacteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646724PMC
February 2009
13 Reads

The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model.

Genet Vaccines Ther 2009 Jan 30;7. Epub 2009 Jan 30.

Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Taiwan.

Background: Tyrosine kinase inhibitor gefitinib is effective against lung cancer cells carrying mutant epidermal growth factor receptor (EGFR); however, it is not effective against lung cancer carrying normal EGFR. The breaking of immune tolerance against self epidermal growth factor receptor with active immunization may be a useful approach for the treatment of EGFR-positive lung tumors. Xenogeneic EGFR gene was demonstrated to induce antigen-specific immune response against EGFR-expressing tumor with intramuscular administration. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-7-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645394PMC
January 2009
8 Reads

Comparative analysis of HIV-1-based lentiviral vectors bearing lyssavirus glycoproteins for neuronal gene transfer.

Genet Vaccines Ther 2009 Jan 13;7. Epub 2009 Jan 13.

Department of Neurosurgery, Emory University, Atlanta, GA, USA.

Background: The delivery of therapeutic genes to the central nervous system (CNS) using viral vectors represents an appealing strategy for the treatment of nerve injury and disorders of the CNS. Important factors determining CNS targeting include tropism of the viral vectors and retrograde transport of the vector particles. Retrograde transport of equine anemia virus (EIAV)-based lentiviral vectors pseudotyped with the glycoprotein derived from the Rabies virus RabERA strain from peripheral muscle to spinal motor neurons (MNs) was previously reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-7-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639530PMC
January 2009
11 Reads

Comparison of electrically mediated and liposome-complexed plasmid DNA delivery to the skin.

Genet Vaccines Ther 2008 Dec 4;6:16. Epub 2008 Dec 4.

Center for Molecular Delivery, University of South Florida, Tampa, FL, USA.

Background: Electroporation is an established technique for enhancing plasmid delivery to many tissues in vivo, including the skin. We have previously demonstrated efficient delivery of plasmid DNA to the skin utilizing a custom-built four-plate electrode. The experiments described here further evaluate cutaneous plasmid delivery using in vivo electroporation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-6-16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631522PMC
December 2008
5 Reads

Genetic immunization with Hantavirus vaccine combining expression of G2 glycoprotein and fused interleukin-2.

Genet Vaccines Ther 2008 Oct 22;6:15. Epub 2008 Oct 22.

Department of Pathogentic Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan city 430030, PR China.

In this research, we developed a novel chimeric HTNV-IL-2-G2 DNA vaccine plasmid by genetically linking IL-2 gene to the G2 segment DNA and tested whether it could be a candidate vaccine. Chimeric gene was first expressed in eukaryotic expression system pcDNA3.1 (+). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-6-15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577087PMC
October 2008
5 Reads

Relative persistence of AAV serotype 1 vector genomes in dystrophic muscle.

Genet Vaccines Ther 2008 Oct 15;6:14. Epub 2008 Oct 15.

Powell Gene Therapy Center, University of Florida, Gainesville, FL, USA.

The purpose of this study was to assess the behavior of pseudotyped recombinant adeno-associated virus type 1 (rAAV2/1) vector genomes in dystrophic skeletal muscle. A comparison was made between a therapeutic vector and a reporter vector by injecting the hindlimb in a mouse model of Limb Girdle Muscular Dystrophy Type 2D (LGMD-2D) prior to disease onset. We hypothesized that the therapeutic vector would establish long-term persistence through prevention of myofiber turnover. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-6-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2572159PMC
October 2008
2 Reads

Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice.

Genet Vaccines Ther 2008 Sep 23;6:13. Epub 2008 Sep 23.

Powell Gene Therapy Center, College of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610-0266, USA.

The AAV9 capsid displays a high natural affinity for the heart following a single intravenous (IV) administration in both newborn and adult mice. It also results in substantial albeit relatively lower expression levels in many other tissues. To increase the overall safety of this gene delivery method we sought to identify which one of a group of promoters is able to confer the highest level of cardiac specific expression and concurrently, which is able to provide a broad biodistribution of expression across both cardiac and skeletal muscle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-0556-6-13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2557000PMC
September 2008
5 Reads

Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line.

Genet Vaccines Ther 2008 Sep 12;6:12. Epub 2008 Sep 12.

Department G402, Pharmacology of Cancer Treatment, German Cancer Research Center, INF 280, D-69120, Heidelberg, Germany.

Background: For many promising target cells (e.g.: haematopoeitic progenitors), the susceptibility to standard adeno-associated viral (AAV) vectors is low. Read More

View Article

Download full-text PDF

Source
http://gvt-journal.biomedcentral.com/articles/10.1186/1479-0
Publisher Site
http://dx.doi.org/10.1186/1479-0556-6-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553401PMC
September 2008
13 Reads